Do you have Alpha-Gal Allergy AND GI symptoms such as abdominal pain, vomiting, and diarrhea? Have you experienced improvement of these symptoms on a mammalian meat-free diet? You may be eligible for our study to help UNC researchers better understand alpha-gal allergy with belly/gastrointestinal symptoms. Compensation provided.

Are you 16 years and older, have Eosinophilic Esophagitis, have tried other therapies but they have not worked, and you have had multiple dilations for narrowing in your throat in the past 12 months? If you meet these criteria then you may be eligible for a study investigating the use of dupilumab to treat EoE patients with severe strictures. Compensation provided.

People with Barrett's esophagus are at higher than average risk of developing esophageal cancer. Obeticholic Acid (OCA) is a medication similar to bile acids (a fluid made and released by the liver). OCA binds to a group of cells in the intestine that is believed to have a positive effect on preventing cancer development. The purpose of this study is to compare the safety and effects of OCA with that of a placebo on the risk of developing esophageal cancer in people with Barrett's esophagus.

We have study goals: (1) To conduct phone interviews to ask about symptoms and life impact from adult patients living with PSC; (2) To lead community advisory board discussions to decide on using existing symptom measures 'as is', modify existing measures or develop new measures to evaluate PSC symptoms; and (3) To conduct interviews with adult patients with PSC to assess their understanding and comprehension of selected symptom measures. We plan to consent and enroll up to 75 patients into a Screening database. From the database, we will select up to 24 patients to interview for Aim 1 and up to 16 patients to interview for Aim 3. Interviews will be conducted over the phone by staff at Duke University. At the end of the study, we will have 3 PSC symptom measures for use in future PSC studies.

Have you been diagnosed with Eosinophilic Esophagitis (EoE) and therapies you've tried don't work, or you aren't interested in taking drugs to treat your EoE? Are you willing to modify your diet to exclude certain foods for 8 weeks? If so, then you may be eligible to participate in a study to see if an individualized diet elimination therapy works to treat EoE.

Do you have any of your baby teeth or are you a parent who has kept your child's baby teeth? Are you a young adult or a parent of a child age 25 or under? Did you know scientists can learn all about different medications, foods, and environmental exposures in a child's early life from their teeth? You may be able to take part in a research study to learn what factors increase children's risk of developing EoE (eosinophilic esophagitis)! We are looking for children and young adults (age 0-25) with or without EoE to volunteer. Compensation will be provided.

To see if a drug administered via injection (dupilumab) is safe and effective at reducing eosinophilic inflammation in the stomach of participants with eosinophilic gastritis (EG)/ eosinophilic gastroenteritis (EGE).

Have you been diagnosed with Barrett's Esophagus or Esophageal Adenocarcinoma? If so, you may be able to participate in a research study to find out if a new, minimally invasive device can collect cells from your esophagus without the need for sedation. Compensation provided.

The purpose of the study is to see if a blood test called GuardantLUNAR-2 can help detect colorectal cancer or other diseases. The main goal of ECLIPSE is to collect health information and blood samples from people who are at average risk for colorectal cancer and are scheduled to have a colonoscopy screening test.

The purpose of this research study is to compare three different FDA approved treatments for fecal incontinence (also known as accidental bowel leakage) in men and women in terms of how well the treatments work, how safe the treatments are, and now much the treatments cost. Patients would undergo Enhanced Medical Management (EMM) for 1 month to optimize bowel function, as we have found EMM controls leakage symptoms in many individuals. Those who do not experience >75% reduction in leakage episodes would then be randomized into biofeedback, SNS, or dextranomer. Patients are followed for two years.The treatments are biofeedback therapy, sacral nerve electrical stimulation (SNS), or dextranomer injections.